Lonza says it plans to invest 14 million Swiss francs ($15 million) to expand antibody-drug conjugate (ADC) manufacturing capacity at the company’s site at Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry, and the deployment of ADC targeted therapies has intensified in recent years, Lonza says. The expansion of the ADC facility will double the existing large-scale manufacturing capacity at Visp while allowing current operations to continue without interruption, Lonza...